AKI Therapeutics A/S financials
AKI Therapeutics A/S
894500E4VTG4S81Y1881 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | DKK 0 | DKK 0 |
| Cost of sales | DKK 0 | DKK 0 |
| Gross profit | DKK 0 | DKK 0 |
| Depreciation & amortisation | DKK 364.6M | DKK 405.0M |
| Operating profit (EBIT) | -DKK 1.23B | -DKK 1.95B |
| Finance costs | DKK 487.8M | DKK 280.7M |
| Profit before tax | -DKK 1.72B | -DKK 2.23B |
| Income tax expense | -DKK 126.1M | -DKK 267.4M |
| Profit for the year | -DKK 1.59B | -DKK 1.96B |
| Total comprehensive income | -DKK 1.59B | -DKK 1.96B |
| Cash flow statement | ||
| Cash generated from operations | -DKK 949.1M | -DKK 1.64B |
| Net cash from operating activities | -DKK 1.44B | -DKK 1.92B |
| Net cash from financing activities | DKK 1.34B | DKK 1.80B |
| Dividends paid | DKK 0 | DKK 0 |
| Repayments of borrowings | DKK 0 | DKK 0 |
| Balance sheet | ||
| Total assets | DKK 1.64B | DKK 2.17B |
| Non-current assets | DKK 1.34B | DKK 1.50B |
| Right-of-use assets | DKK 610.0M | DKK 694.6M |
| Current assets | DKK 300.3M | DKK 671.6M |
| Cash & equivalents | DKK 5.7M | DKK 103.7M |
| Total equity | DKK 551.9M | DKK 806.8M |
| Non-current liabilities | DKK 309.5M | DKK 352.4M |
| Lease liabilities (non-current) | DKK 309.5M | DKK 352.4M |
| Current liabilities | DKK 778.5M | DKK 1.01B |
| Derived metrics | ||
| Return on equity | -288.8% | -243.0% |
| Cash conversion ratio | 0.90× | 0.98× |
| Other reported items | ||
| Adjustments For Decrease Increase In Prepaid Expenses | DKK 0 | DKK 0 |
| Adjustments For Decrease Increase In Trade Account Receivable | DKK 132.0M | -DKK 114.4M |
| Adjustments For Depreciation and Amortisation Expense | DKK 73.0M | DKK 73.0M |
| Adjustments For Finance Income | DKK 0 | DKK 0 |
| Adjustments For Finance Income Cost | -DKK 487.8M | -DKK 280.7M |
| Adjustments For Income Tax Expense | DKK 267.4M | DKK 283.6M |
| Adjustments For Increase Decrease In Other Liabilities | DKK 565.0K | DKK 3.7M |
| Adjustments For Increase Decrease In Trade Account Payable | -DKK 189.9M | DKK 64.5M |
| Cash Advances and Loans From Related Parties | DKK 0 | -DKK 225.0M |
| Current Tax Assets Current | DKK 126.1M | DKK 267.4M |
| Equity and Liabilities | DKK 1.64B | DKK 2.17B |
| Finance Costs Paid Classified As Operating Activities | DKK 487.8M | DKK 280.7M |
| Finance Income Received Classified As Operating Activities | DKK 0 | DKK 0 |
| General and Administrative Expense | DKK 617.5M | DKK 543.1M |
| Increase Decrease In Cash and Cash Equivalents | -DKK 98.0M | -DKK 121.9M |
| Increase Decrease Through Conversion of Convertible Instruments | DKK 1.76B | DKK 2.02B |
| Increase Decrease Through Transactions With Owners | DKK 0 | DKK 0 |
| Intangible Assets Other Than Goodwill | DKK 729.6M | DKK 802.6M |
| Issued Capital | DKK 525.0M | DKK 525.0M |
| Noncurrent Provisions | DKK 0 | DKK 0 |
| Other Comprehensive Income | DKK 0 | DKK 0 |
| Other Current Liabilities | DKK 386.8M | DKK 427.9M |
| Other Noncurrent Receivables | DKK 168.6M | DKK 300.5M |
| Research and Development Expense | DKK 250.0M | DKK 998.7M |
| Reserve of Equity Component of Convertible Instruments | DKK 3.36B | DKK 2.02B |
| Retained Earnings | -DKK 3.74B | -DKK 2.19B |
| Trade and Other Payables To Trade Suppliers | DKK 391.7M | DKK 581.7M |
Every line item above is a fact tagged in AKI Therapeutics A/S's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (DKK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.